At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

A very possible outcome is an investor enjoying 10% sales growth with the potential for the large share buybacks to boost the ...

Central Pacific Financial Corp. faces asset quality strengths but struggles with declining deposits and profitability. Here's ...

For the quarter ended June 30, 2025, BNY Mellon California AMT-Free Municipal Bond Fund’s Class I shares returned -0.83%, ...

Robinhood's growth accelerates with surging options and crypto trading, innovation, and market expansion. Learn why experts ...

DSV A/S saw an increase of 8.8% in inorganic gross profit growth for its Air operations and 9.5% for its Sea operations, ...

The S&P 500 isn’t as diversified as it seems, with a small group of stocks driving most returns. Find out why that matters ...

For the quarter ended June 30, 2025, BNY Mellon AMT-Free Municipal Bond Fund’s Class I shares returned -0.77%, excluding ...

Unclear rules over package exemptions is leading to a pause on shipping of packages by a host of European nations to the U.S.

Markets rallied after Jerome Powell’s speech, signaling a shift in monetary policy that could fuel further gains. See why the ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

TLT and VCLT, historically 90% correlated, have diverged with VCLT outperforming—a gap likely to close as spreads normalize.